Fate Therapeutics Overview
Fate Therapeutics Target Price
Where could FATE trade next? Consensus target price: $5.6.
Get informed when a big investor buys or sells
+ FollowShare Price
$2.31
Average Target Price
$5.63
143.5% upside
143.5% upside4 analysts in the last 4 months
High: $8 | Low: $3.5
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-14 | Piper Sandler | $8 | 246.3% upside |  |
| 2026-08-14 | Wells Fargo | $3.5 | 51.5% upside | |
| 2026-06-08 | H.C. WainwrightDebjit Chattopadhyay | $7 | 203% upside | |
| 2026-05-19 | Jefferies | $4 | 73.2% upside | |
| 2025-03-06 | Stifel Nicolaus | $3 | 29.9% upside | |
| 2024-11-13 | BMO CapitalEtzer Darout | $5 | 116.5% upside | |
| 2024-08-14 | Stifel NicolausBenjamin Burnett | $5 | 116.5% upside | |
| 2024-06-17 | Piper SandlerEdward Tenthoff | $6 | 159.7% upside | |
| 2024-05-16 | H.C. WainwrightDebjit Chattopadhyay | $5 | 116.5% upside | |
| 2024-05-10 | Piper SandlerEdward Tenthoff | $4 | 73.2% upside | |
| 2024-05-10 | BMO CapitalEtzer Darout | $6 | 159.7% upside | |
| 2024-05-10 | Canaccord GenuityBill Maughan | $9 | 289.6% upside | |
| 2023-01-09 | Goldman Sachs | $4 | 73.2% upside | |
| 2023-01-06 | Morgan Stanley | $8 | 246.3% upside | |
| 2023-01-06 | Piper Sandler | $12 | 419.5% upside | |
| 2023-01-06 | BMO Capital | $7 | 203% upside | |
| 2023-01-05 | Truist FinancialRobyn Karnauskas | $7 | 203% upside | |
| 2022-12-15 | Goldman SachsAndrea Tan | $10 | 332.9% upside | |
| 2022-12-13 | Truist Financial | $46 | 1891.3% upside | |
| 2021-12-13 | OppenheimerMatthew Biegler | $135 | 5744.2% upside | |
| 2021-11-08 | CitigroupYigal Nochomovitz | $87 | 3666.2% upside | |
| 2021-11-05 | Roth CapitalAnthony Butler | $60 | 2497.4% upside | |
| 2021-10-25 | JefferiesMichael Yee | $145 | 6177.1% upside | |
| 2021-08-20 | Piper SandlerEdward Tenthoff | $113 | 4791.8% upside | |